The leading Russian pharmaceutical company Binnopharm Group invested approximately 2 billion rubles in its own production projects in the first half of 2024. The main investments were made in the company’s production sites and R&D center.
Binnopharm Group is currently one of the fastest-growing companies. According to the analytical agency AlphaRM, in the first six months of 2024, its growth rate in the pharmacy segment reached an impressive 26%.
Given the growing demand for modern drugs among Russian patients, alongside Binnopharm Group’s foray into the Chinese market and its ongoing commitment to international expansion, the company is persistently investing in the advancement of production and innovation.
This year, our top priority projects include the expansion of the pharmaceutical plant in Zelenograd to initiate the production of highly sought-after drugs based on monoclonal antibodies (MAB), the construction of a state-of-the-art warehouse complex at the Kurgan Sintez, the largest site of the Binnopharm Group, and the enhancement of production capacity on the granulation line at the Alium site in the Moscow Region.
Furthermore, Binnopharm Group is actively advancing its R&D center, established in 2023 in Krasnogorsk, dedicated to developing a facility for the production of highly active drugs (HAP).
Khafiz Gafurov, Financial Director of Binnopharm Group: “The investment strategy of Binnopharm Group is aimed at increasing production volumes and expanding the range of drugs in demand on foreign and Russian markets. To this end, the company is constantly modernizing and automating production processes. In the near future, we expect a significant increase in the company’s operating performance thanks to our investment program.”
